Plain-English translation of NCT06563596 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a combination of three medications—, , and —to treat two types of lymphoma (follicular lymphoma and marginal zone lymphoma) that have either come back or stopped responding to previous treatment. Each of these medications works in a different way to fight cancer cells. The study will help doctors understand whether using all three together is safe and effective for patients like you.
While these three medications are already approved individually or in pairs for lymphoma, doctors want to learn whether combining all three together might work better for patients whose cancer has returned or become resistant to earlier treatments. This combination approach could offer hope to people who have run out of other options.
You likely qualify if…
You likely don't qualify if…
You would visit the clinic for a baseline appointment that includes imaging scans and a bone marrow biopsy to confirm your disease. You would then receive the three medications (likely as pills and possibly infusions) for about one year, with imaging scans repeated at months 3, 6, and 9 to monitor how well the treatment is working. After your year of treatment ends, you would return for an end-of-treatment visit with more scans and a bone marrow biopsy, followed by follow-up appointments every six months for up to 10 years to track your long-term health.
AI-generated summary from trial data · Jun 24, 2026 · Not medical advice
United States